Q3 EPS Estimate for Aardvark Therapeutics Cut by Analyst

Key Points

• HC Wainwright has significantly lowered its Q3 2025 EPS estimate for Aardvark Therapeutics from ($0.51) to ($0.70) per share.
• Wall Street Zen downgraded Aardvark Therapeutics from a "hold" to a "sell" rating, reflecting a shift in analyst sentiment towards the stock.
• Aardvark's stock price has recently dropped by 2.6%, currently trading at $10.17, with a significant gap between its 52-week low of $4.88 and high of $19.58.

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for Aardvark Therapeutics in a note issued to investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.70) per share for the quarter, down from their previous estimate of ($0.51). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics' Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.57) EPS.

Several other brokerages have also recently weighed in on AARD. Wall Street Zen cut Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Royal Bank Of Canada reduced their price target on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research report on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $32.80.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD traded down $0.75 during mid-day trading on Wednesday, hitting $9.02. The company had a trading volume of 65,755 shares, compared to its average volume of 85,450. Aardvark Therapeutics has a 1 year low of $4.88 and a 1 year high of $19.58. The business's 50-day simple moving average is $12.37.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently added to or reduced their stakes in AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Aardvark Therapeutics during the second quarter valued at $42,000. Walleye Capital LLC bought a new stake in Aardvark Therapeutics during the first quarter worth about $88,000. New York State Common Retirement Fund bought a new stake in Aardvark Therapeutics during the second quarter worth about $99,000. Bank of America Corp DE lifted its stake in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock worth $108,000 after purchasing an additional 3,369 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in Aardvark Therapeutics during the first quarter worth about $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.